FAQ

Most AI companies optimize small molecules or antibodies. Evozyne designs entirely new proteins. Our generative models and high-throughput biology produce mechanisms not found in nature and tailored for complex immune diseases.

Generative AI estimates key attributes including potency, specificity, stability, and immunogenicity, and it can separate and optimize individual features. This capability drives breakthroughs such as refined IL-10 engineering and subclass selectivity in IgG.

Immune-mediated diseases where biologics fail or lose effect: IgG-mediated diseases, inflammatory bowel disease, and related immune-driven conditions.

We plan to submit our first IND in 2026.

Engineered proteins can be more selective, tunable, durable, and less immunogenic. They allow mechanisms that antibodies and small molecules cannot deliver.

Peer-reviewed publications in PNAS and microPublication Biology show strong functional improvements in synthetic proteins designed by our models. Additional internal data supports translation to immunology-relevant mechanisms.

EvoGen includes immunogenicity prediction modules. We test early and often for stability, sequence risks, and immunogenic motifs. Validation will occur in the clinic.

Partners gain access to novel mechanisms, a validated AI-native platform, deep immunology insight, and high-throughput experimental capacity. The platform enables multiple shots on goal, not a single asset play.